Naoko Okiyama Selected Research

nuclear matrix protein 2

1/2022	Case of anti-nuclear matrix protein 2 antibody-positive juvenile dermatomyositis preceded by linear cutaneous lupus erythematosus on the face.
1/2022	A 10-year-old girl with low-grade B cell lymphoma complicated by anti-nuclear matrix protein 2 autoantibody-positive juvenile dermatomyositis.
1/2022	Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
1/2022	Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
4/2021	[A case of dermatomyositis positive for anti-nuclear matrix protein 2 antibody without dermatologic symptoms].
1/2021	Clinically amyopathic dermatomyositis associated with anti-nuclear matrix protein 2 antibody.
1/2020	Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.
11/2016	Recent advances in dermatomyositis-specific autoantibodies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naoko Okiyama Research Topics

Disease

18	Myositis (Idiopathic Inflammatory Myopathies) 06/2022 - 08/2009
18	Dermatomyositis (Dermatopolymyositis) 06/2022 - 11/2016
10	Melanoma (Melanoma, Malignant) 01/2022 - 11/2016
9	Neoplasms (Cancer) 06/2022 - 05/2015
7	Dermatitis 12/2022 - 01/2017
6	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2022 - 01/2017
6	Polymyositis 07/2017 - 08/2009
5	Inflammation (Inflammations) 01/2022 - 08/2009
5	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 11/2016
4	Amyopathic dermatomyositis 10/2022 - 11/2016
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 04/2014
3	Erythema 10/2022 - 03/2021
3	Atrophy 01/2022 - 01/2021
3	Necrosis 01/2022 - 01/2021
3	Exanthema (Rash) 01/2022 - 01/2020
3	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2018
3	Muscle Weakness 11/2020 - 11/2016
2	Arthralgia (Joint Pain) 05/2022 - 01/2019
2	Cutaneous Lupus Erythematosus 05/2022 - 01/2022
2	Atopic Dermatitis (Atopic Eczema) 05/2022 - 01/2022
2	Calcinosis 01/2022 - 11/2016
2	Contact Dermatitis (Eczema, Contact) 01/2022 - 05/2015
2	Ulcer 09/2021 - 04/2021
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2021 - 07/2017
2	Vasculitis (Vasculitides) 01/2019 - 04/2016
2	Skin Diseases (Skin Disease) 11/2016 - 05/2015
2	Autoimmune Diseases (Autoimmune Disease) 05/2015 - 09/2014
2	Weight Loss (Weight Reduction) 06/2014 - 04/2014
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2022
1	Diffuse alopecia 05/2022
1	Asthma (Bronchial Asthma) 05/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Diarrhea 01/2022
1	Pruritus (Itching) 01/2022
1	Carcinogenesis 01/2022

Drug/Important Bio-Agent (IBA)

13	AutoantibodiesIBA 06/2022 - 11/2016
10	AntibodiesIBA 05/2022 - 07/2015
10	Proteins (Proteins, Gene)FDA Link 04/2022 - 08/2009
8	nuclear matrix protein 2IBA 01/2022 - 11/2016
6	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2017
5	EnzymesIBA 10/2022 - 11/2016
5	NivolumabIBA 01/2021 - 01/2017
4	Imiquimod (Aldara)FDA LinkGeneric 12/2022 - 01/2020
4	UbiquitinIBA 10/2022 - 11/2016
4	Monoclonal AntibodiesIBA 05/2022 - 08/2012
4	transcriptional intermediary factor 1IBA 01/2022 - 11/2016
4	AutoantigensIBA 01/2021 - 09/2014
4	Interleukin-6 (Interleukin 6)IBA 10/2020 - 08/2009
3	LigandsIBA 06/2022 - 11/2012
3	Staphylococcal Protein A (Protein A)IBA 01/2022 - 01/2020
3	Mi-2 antibodiesIBA 01/2022 - 12/2016
3	Ligases (Synthetase)IBA 11/2021 - 01/2019
3	IpilimumabIBA 01/2021 - 01/2018
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2017 - 08/2012
2	CytokinesIBA 06/2022 - 08/2012
2	InterleukinsIBA 06/2022 - 05/2022
2	Biological ProductsIBA 04/2022 - 05/2015
2	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2022 - 01/2021
2	apremilastIBA 01/2022 - 08/2021
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 04/2021
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 05/2015
2	Alkaline PhosphataseIBA 01/2022 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 03/2021
2	SteroidsIBA 03/2021 - 04/2019
2	PerforinIBA 01/2021 - 10/2010
2	Granzymes (Granzyme)IBA 01/2021 - 01/2018
2	tofacitinibIBA 01/2021 - 04/2014
2	Pharmaceutical PreparationsIBA 12/2020 - 01/2020
2	Immunoglobulins (Immunoglobulin)IBA 06/2020 - 01/2019
2	eribulin FDA Link 06/2018 - 01/2018
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 07/2017 - 07/2015
2	Therapeutic UsesIBA 07/2017 - 08/2009
2	Peptides (Polypeptides)IBA 07/2017 - 07/2015
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2015 - 09/2014
2	Messenger RNA (mRNA)IBA 07/2014 - 08/2012
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 11/2012 - 08/2012
1	ChemokinesIBA 06/2022
1	Interleukin-18 (Interleukin 18)IBA 06/2022
1	Interleukin-13IBA 05/2022
1	AntigensIBA 05/2022
1	RibonucleoproteinsIBA 05/2022
1	dupilumabIBA 05/2022
1	DNA (Deoxyribonucleic Acid)IBA 05/2022
1	Immune Checkpoint ProteinsIBA 04/2022
1	CTLA-4 AntigenIBA 04/2022
1	loricrinIBA 01/2022
1	Phosphodiesterase 4 InhibitorsIBA 01/2022
1	Nucleosomes (Nucleosome)IBA 01/2022
1	HLA-DR Antigens (HLA-DR)IBA 01/2022
1	calcipotriene (calcipotriol)FDA LinkGeneric 01/2022
1	SiliconesIBA 01/2022
1	Coloring Agents (Dyes)IBA 01/2022
1	DinitrofluorobenzeneIBA 01/2022
1	Succimer (Dimercaptosuccinic Acid)FDA Link 01/2022

Therapy/Procedure

9	Therapeutics 09/2021 - 07/2015
3	Drug Therapy (Chemotherapy) 01/2021 - 01/2018
2	Immunotherapy 04/2022 - 09/2021
2	Aftercare (After-Treatment) 03/2021 - 01/2017
2	Hematopoietic Stem Cell Transplantation 01/2021 - 04/2014
1	Breast Implants (Breast Implant) 01/2022